Global

February 10, 2010.

Although representing a huge market, the EU also presents problems that hamper profitability- particularly when it comes to differing price regulations across member states.

January 29, 2010.

January 13, 2010.

Dr Kay Wardle of RSA examines the impact of short-term survival strategies on pre-clinical R&D organizations.

January 06, 2010.

January 04. 2010.

Quintiles' Jim Featherstone asks what the end of the blockbuster generation means for the sales operation?s business model and how pharma should react to the transition.

Reflector reports on how the European pharma commitees and national associations are trying to shape the upcoming pharmaceutical package through informal

With a weak pound being outpaced by the euro, many hospitals are sending drugs to the Continent for higher profits. What can NHS do to stop this practice?

06 August 2009

18 August 2009

11 August

3 August 2009

Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.

16 July 2009

08 July 2009

UK Health Institute leaves guidance unchanged in case against Eisai and Pfizer; more research on NICE methodology needed.

Pharma is wrestling to understand the emerging markets will be the engine of growth for future sales.

12 June 2009

New prediction reflects incremental pressure from economic crisis.

4 June 2009

1 June 2009

Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.

A new report by the Royal College of Physicians breaks down the reasons why patients are disillusioned about access to medicines, and documents a steady growth in the lack of trust between industry and the NHS. More importantly, it gives recommendations on how to solve the problems.

It could be the end of the road for the UK's biotech firms if drastic action isn't taken soon.

EC proposal loosens restrictions on drug packaging and information dissemination.

Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems

Britain's new approach to drug pricing isn't as bad as the industry feared.

UK agency takes the heat for slow evaluations and failing to consider societal benefits of new drugs